Home Prescription Drugs Tags

View the Latest: Prescription Drugs

Filter

List Grid

761 - 770 of 773 Results

  • The Semi-Sad Prospects for Controlling Employer Health Care Costs

    From Drew Altman

    In a commentary on KFF’s 27th employer health benefits survey, President and CEO Dr. Drew Altman discusses the obstacles employers face trying to control their health care costs, and the reasons why they’ve never been meaningful supporters of government cost-containment efforts. He predicts that premium increases expected next year could lead to a new wave of higher deductibles and other forms of cost sharing for the 155 million Americans who rely on employer coverage. Read the column here.

  • Abortion Grows as a Motivator for Midterm Voters, Particularly for Democrats and in States Where It Has Become Illegal Since the Supreme Court Overturned Roe v. Wade

    News Release

    Few Voters Know About the Medicare Drug Provisions in the Inflation Reduction Act, Though Seniors are More Aware and Would Be Likely to Vote for Candidates Who Support Them About a month ahead of the 2022 midterm election, abortion continues to grow as a motivating issue for voters, especially among Democrats and those living in…

  • Probing the Power and Practices of Pharmacy Benefit Managers

    Event Date:
    Event

    Pharmacy benefit managers (PBMs) are increasingly scrutinized intermediaries in the U.S. health care system, negotiating discounts on prescription medications for health insurers and employers while collecting rebates from drugmakers. On June 14, two experts joined KFF’s The Health Wonk Shop and series moderator Larry Levitt in a 45-minute discussion about the power and practices of PBMs.

  • A Small Number of Drugs Account for a Large Share of Medicare Part D Spending

    Issue Brief

    The Inflation Reduction Act requires the federal government to negotiate the price of certain high-spending drugs covered by Medicare. This analysis provides context for understanding the potential impact of negotiating prices for a limited number of Medicare-covered drugs by identifying the 10 top-selling Part D drugs in 2021, measuring the share of total Part D drug spending accounted for by top-selling drugs that year, and examining changes in spending and use of these drugs since 2018.

  • What the Outcome of the Election Could Mean for Medicaid

    Issue Brief

    This brief examines the two presidential candidates’ records and other recent policy proposals that could inform starkly different directions for the program across key areas, including Affordable Care Act (ACA) Medicaid expansion, financing, eligibility, benefits, and cost-sharing, prescription drugs, long-term services and supports, and managed care.

  • Copay Adjustment Programs: What Are They and What Do They Mean for Consumers?

    Issue Brief

    Drug makers sometimes offer copay coupons to lower consumers’ out-of-pocket costs for their brand-name prescriptions, though how private health plans treat those coupons can substantially limit their value to consumers. This issue brief provides an overview of such copay adjustment programs, stakeholder arguments for and against their use, their prevalence, and federal and state efforts to address them.

  • Year in Review: 10 Health Policy Issues for 2023

    Fact Sheet

    This fact sheet offers a look back at 10 issues that KFF tracked closely during 2023 in its polling, policy analysis and journalism, including summaries of major findings and news stories.